Intravenous acyclovir in acute herpes zoster infection.

Abstract

In a double-blind, randomised trial, immune-competent adults with acute herpes zoster received either 5 mg/kg acyclovir (17) or placebo (20) intravenously three times daily. Acyclovir significantly improved rash development, as evidenced by reducing the time of new lesion formation and the times to vesicle collapse and full crusting. Pain at the end of treatment and at three months was less in the treated group but the difference was not statistically significant. Ocular involvement was not affected.

• Authors: J McGill, D R MacDonald, C Fall, G D McKendrick, A Copplestone
• Journal: The Journal of infection (J Infect) Vol. 6 Issue 2 Pg. 157-61 (Mar 1983) ISSN: 0163-4453 [Print] England
• PMID: 6348177 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Acyclovir

Topics

• Acute Disease
• Acyclovir (administration & dosage, therapeutic use)
• Adult
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Herpes Zoster (drug therapy)
• Humans
• Male
• Random Allocation